# Safety Study of a Glycogen Synthase Kinase 3 (GSK3) Inhibitor in Patients With Alzheimer´s Disease

> **NCT00948259** · PHASE1,PHASE2 · COMPLETED · sponsor: **Noscira SA** · enrollment: 30 (actual)

## Conditions studied

- Alzheimer´s Disease

## Interventions

- **DRUG:** NP031112
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00948259
- **Lead sponsor:** Noscira SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2009-11
- **Final completion:** 2009-11
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2009-11-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00948259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00948259, "Safety Study of a Glycogen Synthase Kinase 3 (GSK3) Inhibitor in Patients With Alzheimer´s Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00948259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*